FDAsafety guidance66% confidence
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Mylan Labs; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Hematology · Iron Deficiency Anemia
- Sub-indication
- General
Related signal: FDA Approves Ferric Carboxymaltose ANDA212572 by Mylan Labs